Skip to content

The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))

The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00995501
Enrollment
381
Registered
2009-10-15
Start date
2007-01-31
Completion date
2015-12-31
Last updated
2017-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Perioperative Morbidity

Keywords

steroid administration, tight glucose control, light anesthesiReducing inflammatory response to surgical stress, a

Brief summary

Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anesthesia may decrease perioperative morbidity by reducing the inflammatory response to surgery. Using a three-way factorial approach, the investigators thus propose to test the primary hypotheses that major perioperative morbidity is reduced by: 1) low-dose dexamethasone; 2) intensive perioperative glucose control; and 3) lighter anesthesia. Secondary hypotheses include that each intervention reduces circulating concentrations of the inflammatory marker CRP, and that there is a correlation between C-reactive protein (CRP) and post-operative complications. Anesthetic sensitivity predicts major and minor complications, and delirium Other secondary hypotheses are that each intervention, reduces minor surgical complications, reduces postoperative nausea and vomiting (PONV), reduces postoperative delirium, speeds hospital discharge, improves quality of life (SF-12v2 Health Survey, Christensen's VAS fatigue score), and reduces all-cause one-year mortality.

Detailed description

The perioperative period is characterized by an intense inflammatory response marked by elevated concentrations of inflammatory markers like C-Reactive Protein (CRP). This response has been linked to increased perioperative morbidity and mortality. Available evidence suggests that blunting the inflammatory response to surgical trauma might improve perioperative outcomes. The putative benefits from blunting the surgical stress response are likely to be greatest in high-risk patients such as those having major non-cardiac surgery. We will study three interventions potentially modulating perioperative inflammation, corticosteroids, tight glucose control and light anesthesia and their effects on major morbidity and mortality resulting from major non-cardiac surgery. Steroids are the most powerful routinely available anti-inflammatory drugs. They decrease perioperative concentrations of inflammatory markers and improve outcomes after cardiac and abdominal surgery. Poorly controlled blood glucose worsens the inflammatory response to surgery. Hyperglycemia impairs wound healing, increases infection risk, increases overall hospital mortality, increases the risk of perioperative renal failure, and augments transfusion requirements. Treatment of hyperglycemia has been shown to improve outcomes and decrease mortality in cardiac patients. Also in critically ill patients, it decreased inflammatory markers, overall hospital mortality by 34%, blood stream infections by 46%, and acute renal failure by 41%. Cumulative deep hypnotic time is associated with increased one-year all-cause mortality, possibly through aggravation of the inflammatory response to surgery. In contrast, avoidance of deep anesthesia appears to reduce postoperative CRP levels, the risk of nausea and vomiting, as well as postoperative hemodynamic, respiratory and infectious complications. Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anesthesia may decrease perioperative morbidity by reducing the inflammatory response to surgery. Using a three-way factorial approach, we thus propose to test the primary hypotheses that major perioperative morbidity is reduced by: 1) low-dose dexamethasone; 2) intensive perioperative glucose control; and, 3) lighter anesthesia. Secondary hypotheses include that each intervention reduces circulating concentrations of the inflammatory marker CRP, and that there is a correlation between CRP and post-operative complications. Anesthetic sensitivity predicts major and minor complications, and delirium Other secondary hypotheses are that each intervention, reduces minor surgical complications, reduces postoperative nausea and vomiting (PONV), reduces postoperative delirium, speeds hospital discharge, improves quality of life (SF-12v2 Health Survey, Christensen's VAS fatigue score), and reduces all-cause one-year mortality.

Interventions

DRUGDexamethasone Sodium Sulfate

8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning

DRUGInsulin

Insulin to maintain blood glucose 80-110 mg/dl.

Light anesthesia to maintain BIS about 55

OTHERDexamethasone - placebo

8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning

OTHERInsulin - Placebo

Insulin to maintain blood glucose 180-200 mg/dl.

OTHERAnesthesia management -Placebo

Deep anesthesia to maintain BIS about 35

Sponsors

d sessler
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥40 years old. 2. Major non-cardiac surgical procedures scheduled to take ≥ two hours done under general anesthesia. 3. Written informed consent

Exclusion criteria

1. Recent intravenous or oral steroid therapy (within 30 days); inhaled steroids are permitted 2. Any contraindications to the proposed interventions 3. ASA Physical Status \> 4 4. Non English speaking patients 5. Procedures done under regional anesthesia

Design outcomes

Primary

MeasureTime frameDescription
Major Perioperative Morbidity30 day after surgeryOur primary outcome was a collapsed composite endpoint (any versus none) defined as the occurrence of at least one of sixteen major complications before hospital discharge, including sepsis, severe surgical site infection, myocardial infarction, heart failure, stroke, unstable ventricular arrhythmias, pulmonary embolism, pneumonia, respiratory failure, dialysis dependent renal failure, large pleural or peritoneal effusions, major bleeding, major wound and surgical site healing complications, vascular graft thrombosis, and 30-day mortality.

Secondary

MeasureTime frameDescription
1 Year Mortality1 year after surgeryAll-cause mortality

Countries

United States

Participant flow

Participants by arm

ArmCount
Intensive Glucose Control, Dexamethasone, Light Anesthesia
* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl * Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Light anesthesia target BIS of 55 Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning Insulin: Insulin to maintain blood glucose 80-110 mg/dl. anesthesia management: Light anesthesia to maintain BIS about 55
52
Intensive Glucose Control, Dexamethasone, Deep Anesthesia
* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl * Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Deep anesthesia target BIS of 35 Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning Insulin: Insulin to maintain blood glucose 80-110 mg/dl. Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35
51
Intensive Glucose Control, Placebo, Light Anesthesia
* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl * Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Light anesthesia target BIS of 55 Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning anesthesia management: Light anesthesia to maintain BIS about 55 Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl.
47
Conventional Glucose Control, Dexamethasone, Light Anesthesia
* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl * Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Light anesthesia target BIS of 55 Insulin: Insulin to maintain blood glucose 80-110 mg/dl. anesthesia management: Light anesthesia to maintain BIS about 55 Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
46
Intensive Glucose Control, Placebo, Deep Anesthesia
* Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl * Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Deep anesthesia target BIS of 35 Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl. Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35
46
Conventional Glucose Control, Dexamethasone, Deep Anesthesia
* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl * Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Deep anesthesia target BIS of 35 Insulin: Insulin to maintain blood glucose 80-110 mg/dl. Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35
44
Conventional Glucose Control, Placebo, Light Anesthesia
* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl * Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Light anesthesia target BIS of 55 anesthesia management: Light anesthesia to maintain BIS about 55 Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl.
49
Conventional Glucose Control, Placebo, Deep Anesthesia
* Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl * Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning. * Deep anesthesia target BIS of 35 Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl. Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35
46
Total381

Baseline characteristics

CharacteristicIntensive Glucose Control, Dexamethasone, Light AnesthesiaIntensive Glucose Control, Dexamethasone, Deep AnesthesiaIntensive Glucose Control, Placebo, Light AnesthesiaConventional Glucose Control, Dexamethasone, Light AnesthesiaIntensive Glucose Control, Placebo, Deep AnesthesiaConventional Glucose Control, Dexamethasone, Deep AnesthesiaConventional Glucose Control, Placebo, Light AnesthesiaConventional Glucose Control, Placebo, Deep AnesthesiaTotal
Age, Continuous63 years
STANDARD_DEVIATION 10
65 years
STANDARD_DEVIATION 11
64 years
STANDARD_DEVIATION 11
64 years
STANDARD_DEVIATION 11
65 years
STANDARD_DEVIATION 13
64 years
STANDARD_DEVIATION 11
63 years
STANDARD_DEVIATION 12
65 years
STANDARD_DEVIATION 12
64 years
STANDARD_DEVIATION 11
Body mass index28 kg/m^2
STANDARD_DEVIATION 4
30 kg/m^2
STANDARD_DEVIATION 6
28 kg/m^2
STANDARD_DEVIATION 6
28 kg/m^2
STANDARD_DEVIATION 8
28 kg/m^2
STANDARD_DEVIATION 6
27 kg/m^2
STANDARD_DEVIATION 5
27 kg/m^2
STANDARD_DEVIATION 6
29 kg/m^2
STANDARD_DEVIATION 6
28 kg/m^2
STANDARD_DEVIATION 6
Race/Ethnicity, Customized
African American
2 Participants2 Participants5 Participants1 Participants2 Participants1 Participants1 Participants4 Participants18 Participants
Race/Ethnicity, Customized
White
49 Participants49 Participants42 Participants45 Participants44 Participants43 Participants48 Participants42 Participants362 Participants
Sex: Female, Male
Female
22 Participants14 Participants19 Participants13 Participants16 Participants13 Participants17 Participants13 Participants127 Participants
Sex: Female, Male
Male
30 Participants37 Participants28 Participants33 Participants30 Participants31 Participants32 Participants33 Participants254 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
deaths
Total, all-cause mortality
1 / 527 / 519 / 477 / 467 / 467 / 445 / 492 / 46
other
Total, other adverse events
15 / 5225 / 5120 / 4717 / 4622 / 4621 / 4420 / 4924 / 46
serious
Total, serious adverse events
10 / 5210 / 518 / 479 / 4610 / 468 / 4411 / 499 / 46

Outcome results

Primary

Major Perioperative Morbidity

Our primary outcome was a collapsed composite endpoint (any versus none) defined as the occurrence of at least one of sixteen major complications before hospital discharge, including sepsis, severe surgical site infection, myocardial infarction, heart failure, stroke, unstable ventricular arrhythmias, pulmonary embolism, pneumonia, respiratory failure, dialysis dependent renal failure, large pleural or peritoneal effusions, major bleeding, major wound and surgical site healing complications, vascular graft thrombosis, and 30-day mortality.

Time frame: 30 day after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intensive Glucose Control, Dexamethasone, Light AnesthesiaMajor Perioperative Morbidity10 Participants
Intensive Glucose Control, Dexamethasone, Deep AnesthesiaMajor Perioperative Morbidity10 Participants
Intensive Glucose Control, Placebo, Light AnesthesiaMajor Perioperative Morbidity8 Participants
Conventional Glucose Control, Dexamethasone, Light AnesthesiaMajor Perioperative Morbidity9 Participants
Intensive Glucose Control, Placebo, Deep AnesthesiaMajor Perioperative Morbidity10 Participants
Conventional Glucose Control, Dexamethasone, Deep AnesthesiaMajor Perioperative Morbidity8 Participants
Conventional Glucose Control, Placebo, Light AnesthesiaMajor Perioperative Morbidity11 Participants
Conventional Glucose Control, Placebo, Deep AnesthesiaMajor Perioperative Morbidity9 Participants
Comparison: Compare 4 arms with intensive glucose control vs. 4 arms with conventional glucose controlp-value: 0.8699.6% CI: [0.45, 2]Regression, Logistic
Comparison: Compare 4 arms with Dexamethasone vs. 4 arms with Placebop-value: 0.8799.6% CI: [0.45, 2]Regression, Logistic
Comparison: Compare 4 arms with light anesthesia vs. 4 arms with deep anesthesiap-value: 0.999.6% CI: [0.49, 2.2]Regression, Logistic
Secondary

1 Year Mortality

All-cause mortality

Time frame: 1 year after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intensive Glucose Control, Dexamethasone, Light Anesthesia1 Year Mortality1 Participants
Intensive Glucose Control, Dexamethasone, Deep Anesthesia1 Year Mortality7 Participants
Intensive Glucose Control, Placebo, Light Anesthesia1 Year Mortality9 Participants
Conventional Glucose Control, Dexamethasone, Light Anesthesia1 Year Mortality7 Participants
Intensive Glucose Control, Placebo, Deep Anesthesia1 Year Mortality7 Participants
Conventional Glucose Control, Dexamethasone, Deep Anesthesia1 Year Mortality7 Participants
Conventional Glucose Control, Placebo, Light Anesthesia1 Year Mortality5 Participants
Conventional Glucose Control, Placebo, Deep Anesthesia1 Year Mortality2 Participants
Comparison: Compare 4 arms with intensive glucose control vs. 4 arms with conventional glucose controlp-value: 0.899.6% CI: [0.37, 2.3]Regression, Logistic
Comparison: Compare 4 arms with Dexamethasone vs. 4 arms with Placebop-value: 0.8499.6% CI: [0.43, 2.7]Regression, Logistic
p-value: 0.8799.6% CI: [0.42, 2.7]Regression, Logistic

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026